Why the study?
Is CYP2C19 genotype-guided de-escalation feasible and efficient in an all-comers ACS population?
Is CYP2C19 genotype-guided de-escalation feasible and efficient in an all-comers ACS population?
Point-of-care CYP2C19 genotyping is a feasible and efficient strategy for guiding rapid de-escalation of antiplatelet therapy from ticagrelor to clopidogrel in patients with acute coronary syndrome.
Supports POC CYP2C19 testing for rapid de-escalation in ACS; leaves open outcome benefits pending RCTs.
CYP2C19 genotype-guided-de-escalation in an all-comers ACS population is feasible. POC genotyping leads to shorter turnaround times and quicker de-escalation. Time to de-escalation from ticagrelor to clopidogrel in noncarriers was short, with high physician adherence to genotype results.
No takes yet. Share an insight, caveat, or question.
Azzahhafi et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: